Candel Therapeutics Inc (CADL) concluded trading on Wednesday at a closing price of $8.00, with 4.38 million shares of worth about $35.06 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 9.74% during that period and on January 15, 2025 the price saw a gain of about 2.04%. Currently the company’s common shares owned by public are about 32.13M shares, out of which, 27.66M shares are available for trading.
Stock saw a price change of -4.19% in past 5 days and over the past one month there was a price change of -18.37%. Year-to-date (YTD), CADL shares are showing a performance of -7.83% which increased to 501.50% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.16 but also hit the highest price of $14.60 during that period. The average intraday trading volume for Candel Therapeutics Inc shares is 3.61 million. The stock is currently trading -3.54% below its 20-day simple moving average (SMA20), while that difference is up 26.57% for SMA50 and it goes to 20.82% higher than SMA200.
Candel Therapeutics Inc (NASDAQ: CADL) currently have 32.13M outstanding shares and institutions hold larger chunk of about 16.09% of that.
The stock has a current market capitalization of $355.81M and its 3Y-monthly beta is at -1.17. It has posted earnings per share of -$1.74 in the same period. It has Quick Ratio of 1.18. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for CADL, volatility over the week remained 11.55% while standing at 14.67% over the month.
Analysts are in expectations that Candel Therapeutics Inc (CADL) stock would likely to be making an EPS of 0 in the current quarter, while forecast for next quarter EPS is 0 and it is 0 for next year. For the current quarter EPS, analysts have given the company a lowest target 0 which is 0 at the higher side of the target for the same. Stock’s fiscal year EPS is expected to drop by -21.37% while it is estimated to increase by 15.09% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by H.C. Wainwright on December 02, 2022 offering a Buy rating for the stock and assigned a target price of $11 to it. Coverage by BMO Capital Markets stated Candel Therapeutics Inc (CADL) stock as an Outperform in their note to investors on November 19, 2021, suggesting a price target of $18 for the stock. On August 23, 2021, UBS Initiated their recommendations, while on August 23, 2021, Jefferies Initiated their ratings for the stock with a price target of $22. Stock get an Outperform rating from Credit Suisse on August 23, 2021.
